Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900919 | 0.94 | ADORA1 (0.47) | HRH3ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL4904056 | 0.75 | ADORA1 (0.39) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL4907739 | 0.74 | HRH3 (0.48) | HRH3ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL4900909 | 0.74 | ADORA1 (0.40) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL1332972 | 0.68 | ADORA1 (0.52) | ADORA1ADORA2A | |
| SCHEMBL6847089 | 0.67 | PRKD3 (0.54) | — | |
| SCHEMBL11256796 | 0.67 | HRH1 (0.60) | DRD2DRD3 | |
| SCHEMBL3070853 | 0.67 | MEN1 (0.44) | HRH3ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL14335032 | 0.66 | HRH3 (0.40) | HRH3DRD2DRD3 | |
| SCHEMBL18837264 | 0.66 | LTA4H (0.56) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | HRH3 2604/4885ADORA1 680/4885ADORA2A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.